Neurent Medical reportedly sniffed out a funding round of nearly $12 million for the minimally invasive rhinitis treatment it’s developing.
The €9.3 million round for Oranmore, Ireland-based Neurent was led by Irish venture capital shop Fountain Healthcare Partners and included participation from Atlantic Bridge, Ireland’s Western Development Commission, Enterprise Ireland and a syndicate of U.S. and Irish medical device veterans, the Irish Times reported.
According to its website, the single-use Neurent device uses radiofrequency energy to “interrupt the autonomic function within the mucosal structures of nasal cavities which will reverse the inflammatory cascade” in a minimally invasive, outpatient procedure to treat chronic runny nose. The technology, designed to deliver three years of relief without medication, is based on a high-risk but effective treatment from the 1950s, co-f0under & CEO Brian Shields told the newspaper.
“The outcome was brilliant back then, if you weren’t blinded by the procedure or dead,” Shields said, adding that the cash infusion is enough to hire 25 workers and see the company through to a bid for FDA approval. The company hopes to launch the first of a pair of clinical studies in 2019, according to the paper.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.